Immune cells engineered to hunt thymus cancer show promise in early trial

NCT ID NCT07598955

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether specially engineered immune cells (CAR-NK cells) can safely treat people with advanced thymus cancers that have not responded to other treatments. Participants will receive cells that target one of three proteins found on their tumor. The goal is to find the right dose and see if the cells shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-NK cells (immune cells engineered to attack cancer)
What this could lead to: If successful, this could provide a new treatment option for people with hard-to-treat thymus cancers that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply to everyone. There are risks of severe side effects from the cells or the chemotherapy given beforehand.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B2 THYMOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cortical thymoma thymic carcinoma thymic epithelial neoplasm thymoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B2 THYMOMA THYMIC CARCINOMA

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.